<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04983849</url>
  </required_header>
  <id_info>
    <org_study_id>Prot. RCT 001/2021</org_study_id>
    <nct_id>NCT04983849</nct_id>
  </id_info>
  <brief_title>Evaluation of Metronidazole Hydrogel 25% in Stage II and III Periodontitis</brief_title>
  <official_title>Evaluation of Effects of Subgingival Administration of Metronidazole Hydrogel 25% in Stage II and III Periodontitis: Randomized, Split Mouth, Single-blind Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of L'Aquila</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of L'Aquila</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized clinical trial will be performed single-blind to evaluate the effectiveness of&#xD;
      sublingual metronidazole hydrogel 25 % in periodontitis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized clinical trial will be performed single-blind to evaluate the effectiveness of&#xD;
      sublingual metronidazole hydrogel 25 % in periodontitis in stage II and III.&#xD;
&#xD;
      At least 40 volunteers between the age of 18 and 80, will be enlisted, with the need to&#xD;
      perform the SRP. In half of the mouth will be used the metronidazole hydrogel 25%, while in&#xD;
      the other half no drugs will be used of delivered.&#xD;
&#xD;
      The study will be carried out in accordance with the Helsinki Declaration and the Protocol&#xD;
      will be submitted to the Internal Review Board of the University to obtain authorization.&#xD;
      Afterwards, the protocol will be recorded on the databa-se clinicaltrials.gov for clinical&#xD;
      trials.&#xD;
&#xD;
      The protocol respects the SPIRIT parameters for the compilation of protocols on clinical&#xD;
      trials and the study will respect the parameters of CONSORT sta-tement on randomized clinical&#xD;
      trials.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 7, 2021</start_date>
  <completion_date type="Actual">July 7, 2021</completion_date>
  <primary_completion_date type="Actual">July 7, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MMP8, MMP9</measure>
    <time_frame>baseline - 1 week</time_frame>
    <description>matrix metalloproteinases</description>
  </primary_outcome>
  <primary_outcome>
    <measure>IL1, IL6,IL8,IL17</measure>
    <time_frame>baseline - 1 week</time_frame>
    <description>interleukin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>TNF alfa</measure>
    <time_frame>baseline - 1 week</time_frame>
    <description>tumor necrosis factor alfa</description>
  </primary_outcome>
  <primary_outcome>
    <measure>RANK-L</measure>
    <time_frame>baseline - 1 week</time_frame>
    <description>Receptor activator of nuclear factor kappa-Β ligand</description>
  </primary_outcome>
  <primary_outcome>
    <measure>OPG</measure>
    <time_frame>baseline - 1 week</time_frame>
    <description>osteoprotegerin</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CAL</measure>
    <time_frame>baseline - 1 week</time_frame>
    <description>clinical attack level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PPD</measure>
    <time_frame>baseline - 1 week</time_frame>
    <description>Probing Pocket Depth</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GI</measure>
    <time_frame>baseline - 1 week</time_frame>
    <description>gingival index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FMPS</measure>
    <time_frame>baseline - 1 week</time_frame>
    <description>full mouth plaque score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FMBS</measure>
    <time_frame>baseline - 1 week</time_frame>
    <description>full mouth bleeding score</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>MMP8, MMP9</condition>
  <condition>IL1, IL6, IL8, IL17</condition>
  <condition>TNF ALFA</condition>
  <condition>RANK-L</condition>
  <condition>OPG</condition>
  <condition>CAL</condition>
  <condition>PPD</condition>
  <condition>GI</condition>
  <condition>FMPS</condition>
  <condition>FMBS</condition>
  <arm_group>
    <arm_group_label>hydrogel metronidazole 25%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>metronidazole hydrogel in adjunct to non surgical periodontal therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>scaling and root planing</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>the only use of scaling and root planing</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>metronidazole hydrogel</intervention_name>
    <description>scaling and root planning in adjunct to the use of metronidazole in the periodontal pocket</description>
    <arm_group_label>hydrogel metronidazole 25%</arm_group_label>
    <other_name>Non Surgical Periodontal Therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>scaling and root planning</intervention_name>
    <description>scaling and root planning</description>
    <arm_group_label>scaling and root planing</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  10% of sites with survey depth 5 mm&#xD;
&#xD;
          -  Comparable pockets in 4 mouth quadrants&#xD;
&#xD;
          -  Health at systemic level&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Changes in oral mucosa&#xD;
&#xD;
          -  Depth at the poll 5 mm&#xD;
&#xD;
          -  Presence of removable prostheses or orthodontic equipment&#xD;
&#xD;
          -  Allergies to even a single component of a product in testing• Antibiotic-based&#xD;
             treatments during the 6 months preceding the start of testing&#xD;
&#xD;
          -  History of previous periodontal treatments in the 12 months preceding the start of the&#xD;
             study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of L'Aquila, division of periodontology</name>
      <address>
        <city>L'Aquila</city>
        <zip>67100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 20, 2021</study_first_submitted>
  <study_first_submitted_qc>July 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 30, 2021</study_first_posted>
  <last_update_submitted>July 20, 2021</last_update_submitted>
  <last_update_submitted_qc>July 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of L'Aquila</investigator_affiliation>
    <investigator_full_name>Enrico Marchetti</investigator_full_name>
    <investigator_title>Prof. Enrico Marchetti</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Periodontitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metronidazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

